Filtern
Volltext vorhanden
- ja (3)
Gehört zur Bibliographie
- ja (3)
Dokumenttyp
Schlagworte
- clinical study (3) (entfernen)
Institut
- Lehrstuhl für Orthopädie (3) (entfernen)
Handgelenkserkrankungen haben sowohl in Amerika wie auch in Europa mit steigenden Fallzahlen einen durch den Ausfall der Arbeitskraft nicht unerheblichen Einfluß auf die Volkswirtschaft. Ständige Wiederholungen in hoher Frequenz werden für die RSI ursächlich verantwortlich gemacht. Basierend auf der Annahme, dass Vibrationen und Beschleunigungskräften mittels Dämpfkörpern beeinflusst werden können, wurde die Coopercare Lastrap-Bandage entwickelt. Obwohl die Behandlung mit Handgelenksorthesen eine allgemein gängige Form der Behandlung von verschiedenen Handgelenkserkrankungen darstellt, gibt es hierzu nur sehr wenige klinische Daten über den Stellenwert dieser Verfahren. Daher wurde in einer prospektiven randomisierten Längsschnitt-Studie der Stellenwert einer Bandagenbehandlung mit biomechanisch begründetem Ansatz im Vergleich zur konventionellen Bandagentherapie an 34 Patienten mit unterschiedlichen Erkrankungen des Handgelenks getestet. Unserer Studie zufolge sind entsprechend dem biomechanischen Ansatz die unter 40-jährigen männlichen Patienten mit seit kurzem bestehender Tendovaginitis die Zielgruppe, die am Besten von einer Bandagentherapie mit der Lastrap®-Bandage profitieren. Bei unter 40-jährigen männlichen Patienten mit Distorsion des Handgelenks ist die Manu-Hit®-Bandage zu bevorzugen. Durch die deutliche Schmerzreduktion können hier Handgelenksorthesen unter anderem den Gebrauch von NSAR verringern und damit die Arzneimittelausgaben senken.
Background:
The standardized maritime pine bark extract (Pycnogenol\(^{®}\)) has previously shown symptom alleviating effects in patients suffering from moderate forms of knee osteoarthritis (OA). The cellular mechanisms for this positive impact are so far unknown. The purpose of the present randomized pilot controlled study was to span the knowledge gap between the reported clinical effects of Pycnogenol\(^{®}\) and its in vivo mechanism of action in OA patients.
Methods:
Thirty three patients with severe OA scheduled for a knee arthroplasty either received 100 mg of Pycnogenol\(^{®}\) twice daily or no treatment (control group) three weeks before surgery. Cartilage, synovial fluid and serum samples were collected during surgical intervention. Relative gene expression of cartilage homeostasis markers were analyzed in the patients' chondrocytes. Inflammatory and cartilage metabolism mediators were investigated in serum and synovial fluid samples.
Results:
The oral intake of Pycnogenol\(^{®}\) downregulated the gene expression of various cartilage degradation markers in the patients' chondrocytes, the decrease of MMP3, MMP13 and the pro-inflammatory cytokine IL1B were statistically significant (p ≤ 0.05). Additionally, protein concentrations of ADAMTS-5 in serum were reduced significantly (p ≤ 0.05) after three weeks intake of the pine bark extract.
Conclusions:
This is the first report about positive cellular effects of a dietary supplement on key catabolic and inflammatory markers in patients with severe OA. The results provide a rational basis for understanding previously reported clinical effects of Pycnogenol\(^{®}\) on symptom scores of patients suffering from OA.
Hypophosphatasia (HPP) is a rare, inherited, metabolic disease characterized by tissue‐nonspecific alkaline phosphatase deficiency resulting in musculoskeletal and systemic clinical manifestations. This observational study evaluated the effectiveness of enzyme replacement therapy with asfotase alfa on physical function and health‐related quality of life (HRQoL) among adults with pediatric‐onset HPP who received asfotase alfa for 12 months at a single center (ClinicalTrial.gov no.: NCT03418389). Primary outcomes evaluated physical function with the 6‐minute walk test (6MWT), timed up‐and‐go (TUG) test, Short Physical Performance Battery (SPPB), and handheld dynamometry (HHD). Secondary outcome measures included the Lower Extremity Functional Scale (LEFS), pain prevalence/intensity, and pain medication use; HRQoL was evaluated using the 36‐Item Short‐Form Health Survey version 2 (SF‐36v2). Safety data were collected throughout the study. All 14 patients (11 women) had compound heterozygous ALPL gene mutations and ≥1 HPP bone manifestation, including history of ≥1 fracture. Mean (min, max) age was 51 (19 to 78) years. From baseline to 12 months of treatment, median 6MWT distance increased from 267 m to 320 m (n = 13; p = 0.023); median TUG test time improved from 14.4 s to 11.3 s (n = 9; p = 0.008). Specific components of the SPPB also improved significantly: median 4‐m gait speed increased from 0.8 m/s to 1.1 m/s (n = 10; p = 0.007) and median repeated chair‐rise time improved from 22 s to 13 s (n = 9; p = 0.008). LEFS score improved from 24 points to 53 points (n = 10; p = 0.002). Improvements in HHD were not clinically significant. SF‐36v2 Physical Component Score (PCS) improved after 12 months of treatment (n = 9; p = 0.010). Pain level did not change significantly from baseline to 12 months of treatment. There were significant improvements on chair‐rise time and SF‐36v2 PCS by 3 months, and on TUG test time after 6 months. No new safety signals were identified. These results show the real‐world effectiveness of asfotase alfa in improving physical functioning and HRQoL in adults with pediatric‐onset HPP. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.